Form 8-K - Current report
10 Mai 2024 - 1:17PM
Edgar (US Regulatory)
false 0001744659 0001744659 2024-05-10 2024-05-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2024
Akero Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-38944 |
|
81-5266573 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
601 Gateway Boulevard, Suite 350 South San Francisco, CA |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (650) 487-6488
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
AKRO |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition |
On May 10, 2024, Akero Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: May 10, 2024 |
|
AKERO THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Andrew Cheng |
|
|
|
|
Name: |
|
Andrew Cheng, M.D., Ph.D. |
|
|
|
|
Title: |
|
President and Chief Executive Officer |
Exhibit 99.1
Akero Therapeutics Reports First Quarter 2024 Financial Results and
Provides Business Update
Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with
pre-cirrhotic MASH reported during the first quarter of 2024
Phase 3
SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with
compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024
SOUTH SAN FRANCISCO, Calif. May 10, 2024
/GLOBE NEWSWIRE/ Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter
financial results for the period ending March 31, 2024 and provided business updates.
We continued to make significant advancements in the
clinical development of EFX during the first quarter of this year, said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. The increased improvements in fibrosis stage observed from weeks 24 to 96 in the Phase 2b
HARMONY study in patients with pre-cirrhotic MASH (F2-F3) showed EFXs potential to result in higher rates of fibrosis improvement after longer treatment. With over
$900 million in cash, cash equivalents, and short term marketable securities following a March 2024 equity offering, we are well-positioned to progress our Phase 3 SYNCHRONY program through primary endpoint readout for our two studies in
patients with pre-cirrhotic MASH and fund Akeros current operating plan into the second half of 2027.
Phase 2b HARMONY Study Week 96 Analysis
|
|
|
In March 2024, Akero reported Week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety
of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3). |
|
|
|
The study previously met its primary endpoint of ≥1 stage improvement in fibrosis with no worsening of MASH
after 24 weeks of treatment for both the 50mg EFX (41%) and 28mg EFX (39%) dose groups, compared to 20% for the placebo arm. |
|
|
|
At week 96, the response rates on this endpoint increased to 75% (p<0.001) for 50mg EFX and 46% (p=0.07) for
28mg EFX, compared to 24% for placebo. |
|
|
|
The study also demonstrated additional improvements on histology endpoints at week 96, including:
|
|
|
|
36% (p<0.01) and 31% (p<0.01) of patients treated with 50mg EFX and 28mg EFX experienced a 2-stage improvement in fibrosis without worsening of MASHmore than 10-fold the placebo rate of 3%. |
|
|
|
68% (p<0.001) and 27% (p=0.053) of patients with F3 fibrosis at baseline in the 50mg EFX and 28mg EFX groups
experienced ≥1 stage improvement in fibrosis without worsening of MASH, compared with 14% for placebo. |
|
|
|
Statistically significant effects were also observed for multiple secondary endpoints in both dose groups,
including improvements in liver enzymes, non-invasive fibrosis markers, glycemic control, and lipoproteins. |
|
|
|
Treatment with EFX was generally well-tolerated, with a tolerability profile comparable to that observed at week
24 in the HARMONY study. A total of three patients treated with EFX were discontinued due to adverse events between week 24 and week 96 (two in the 28mg group and one in the 50mg group), compared with none for placebo. |
Phase 2b SYMMETRY Study
|
|
|
The ongoing Phase 2b SYMMETRY study, which is evaluating the efficacy and safety of EFX in patients with
compensated cirrhosis due to MASH (F4), remains on track to report week 96 results in the first quarter of 2025. |
Phase 3 SYNCHRONY
Program
|
|
|
Akeros Phase 3 SYNCHRONY clinical trial program consists of three trials, two of which started enrolling
patients in December 2023 and the third of which remains on track to be initiated in the second quarter of 2024. |
|
|
|
SYNCHRONY Histology is evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic MASH (F2-F3) and is currently expected to enroll approximately 1,000 patients to receive weekly injections of EFX 28mg, EFX 50mg, or placebo. The primary
endpoint, designed to support an application for accelerated approval, is the proportion of patients experiencing ≥ 1-stage fibrosis improvement AND resolution of MASH after 52 weeks of treatment. After
52 weeks, patients will continue treatment as randomized in SYNCHRONY Histology to be followed for long-term clinical outcomes, such as progression to cirrhosis. |
|
|
|
SYNCHRONY Real-World is currently expected to enroll approximately 700 patients with MASH or metabolic
dysfunction-associated steatotic liver disease (MASLD) diagnosed by either histology or non-invasive tests to receive weekly injections of EFX 50mg or placebo, including up to 100 patients rolled over from
Phase 2b studies of EFX. The primary endpoint of safety and tolerability will be assessed after 52 weeks of treatment. |
|
|
|
SYNCHRONY Outcomes, which remains on track to be initiated in the second quarter of 2024, will evaluate
the safety and efficacy of EFX in patients with compensated cirrhosis due to MASH (F4). |
|
|
|
In all EFX Phase 3 studies, patients will use the LyoJect 3S dual chamber syringe, a pre-filled device designed for patient self-administration. This optimized formulation delivers blood levels of EFX comparable to those of the liquid formulation used in prior clinical studies.
|
Public Offering of Common Stock
|
|
|
In March 2024, Akero announced the closing of its upsized, underwritten public offering of 12,650,000 shares of
its common stock at a public offering price of $29.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering. |
|
|
|
Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering
expenses, were approximately $366.9 million. |
First Quarter 2024 Financial Results
|
|
|
Akeros cash, cash equivalents and short-term marketable securities as of March 31, 2024, were
$903.7 million. |
|
|
|
Akero believes that its current cash, cash equivalents, and short-term marketable securities will be sufficient
to fund its Phase 3 SYNCHRONY Histology and Real-World studies through their respective primary endpoints and Akeros current operating plan into the second half of 2027. |
|
|
|
Research and development expenses for the three-month period ended March 31, 2024 were $50.7 million,
compared to $21.8 million for the comparable period in 2023. These increases are attributable to higher expenses associated with the completion of the Phase 2b HARMONY study, the ongoing SYMMETRY study, initiation of the Phase 3 SYNCHRONY
Histology and SYNCHRONY Real-World studies, manufacturing required to support Phase 3 and potential marketing applications, as well as higher expenses for personnel. |
|
|
|
General and administrative expenses for the three-month period ended March 31, 2024 were $9.3 million,
compared to $7.0 million for the comparable period in 2023. These increases are attributable to higher expenses for personnel, and professional services and other costs associated with operating as a public company. |
|
|
|
Total operating expenses were $60.0 million for the three-month period ended March 31, 2024, compared
to $28.8 million for the comparable period in 2023. |
About Efruxifermin
Efruxifermin (EFX), Akeros lead product candidate for MASH, is a differentiated Fc-FGF21 fusion protein that has
been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX appears to reduce liver fat and inflammation, reverse
fibrosis, increase insulin sensitivity and improve lipids. This holistic approach offers the potential to address the complex, multi-system disease state of MASH, including improvements in lipoprotein risk factors linked to cardiovascular disease
the leading cause of death in MASH patients. EFX is designed to offer convenient once-weekly dosing and has been generally well tolerated in clinical trials to date.
About MASH
MASH is a serious form of MASLD that is
estimated to affect more than 17 million Americans. MASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis,
liver failure, cancer and eventually death. MASH is the fastest growing cause of liver transplants and liver cancer in the US and Europe.
About Akero
Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases
marked by high unmet medical need, including MASH. Akeros lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with
compensated cirrhosis due to MASH (F4 fibrosis), as well as two ongoing Phase 3 clinical trials: the SYNCHRONY Histology study in patients with pre-cirrhotic MASH
(F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical trial, the SYNCHRONY Outcomes study
in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be initiated in the second quarter of 2024. The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us
at akerotx.com and follow us on LinkedIn and X for more information.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to,
statements regarding Akeros business plans and objectives, including future plans or expectations for EFX and clinical trial design; the therapeutic effects of EFX; the timing and initiation of Akeros Phase 3 SYNCHRONY program; upcoming
milestones, including week 96 results of the Phase 2b SYMMETRY study; the anticipated benefits and optimization of the LyoJect 3S dual chamber syringe; and Akeros growth as a company and expectations regarding its uses of capital, expenses,
and financial results, including the expected cash runway. Any forward-looking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of
Akeros product candidate development activities and planned clinical trials; Akeros ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical
studies; regulatory developments in the United States and foreign countries; Akeros ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption Risk Factors in Akeros most
recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential
risks, uncertainties and other important factors in Akeros other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation
to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com
Media Contact:
Sarah OConnell
732.456.0092
soconnell@vergescientific.com
Akero Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
|
December 31, 2023 |
|
Assets |
|
|
|
|
|
|
|
|
Cash, cash equivalents and short-term marketable securities |
|
$ |
903,665 |
|
|
$ |
550,010 |
|
Other current assets |
|
|
7,615 |
|
|
|
9,952 |
|
Non-current assets |
|
|
963 |
|
|
|
20,309 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
912,243 |
|
|
$ |
580,271 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders Equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
$ |
30,259 |
|
|
$ |
19,128 |
|
Non-current liabilities |
|
|
35,731 |
|
|
|
25,837 |
|
Stockholders equity |
|
|
846,253 |
|
|
|
535,306 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
912,243 |
|
|
$ |
580,271 |
|
|
|
|
|
|
|
|
|
|
Akero Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except
share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2024 |
|
|
2023 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
$ |
50,650 |
|
|
$ |
21,787 |
|
General and administrative |
|
|
9,304 |
|
|
|
6,966 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
59,954 |
|
|
|
28,753 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(59,954 |
) |
|
|
(28,753 |
) |
Interest expense |
|
|
(991 |
) |
|
|
(457 |
) |
Interest and other income, net |
|
|
7,601 |
|
|
|
3,379 |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(53,344 |
) |
|
$ |
(25,831 |
) |
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
$ |
(53,693 |
) |
|
$ |
(25,847 |
) |
|
|
|
|
|
|
|
|
|
Net loss per common share, basic and diluted |
|
$ |
(0.90 |
) |
|
$ |
(0.55 |
) |
|
|
|
|
|
|
|
|
|
Weighted-average number of shares used in computing net loss per common share, basic and
diluted |
|
|
59,307,759 |
|
|
|
46,944,059 |
|
|
|
|
|
|
|
|
|
|
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Akero Therapeutics (NASDAQ:AKRO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Akero Therapeutics (NASDAQ:AKRO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024